Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-10 01:38:52 EDT

Explore

PostsPeople
LatestRanked
@vanjohn10.bsky.socialOct 5, 2026, 5:32 PM

CEO Dr. James Bianco provides background to the patent announcement earlier today. He introduces TuHURA’s ADC program and explains how it can address immunosuppressive MDSCs and block the VISTA checkpoint inhibitor.
$HURA
#ImmunoOncology #CancerResearch #LifeSciences
youtu.be/rT1RLh6db8Y

@vanjohn10.bsky.socialOct 2, 2026, 9:11 PM

If TuHURA is successful with its deep-seated tumor trial in Merkel cell carcinoma, it could expand IFx-2.0's addressable market by 30%. Join CEO Dr. James Bianco as he explains.
$HURA
#ImmunoOncology #CancerResearch #LifeSciences
youtube.com/shorts/vl5dw...

@vanjohn10.bsky.socialSep 26, 2026, 8:37 PM

Tuhura Biosciences has a second program for IFx-2.0 in deep seated tumors. If successful, this approach could expand the population that may benefit from IFx. Join CEO Dr. James Bianco as he explains how it's done.
$HURA #ImmunoOncology #CancerResearch #LifeSciences
youtube.com/shorts/S1twF...

@genoway.bsky.socialSep 22, 2026, 12:04 PM

Meet genOway at the 85th Annual Meeting of the Japanese Cancer Association! 🇯🇵
Sept 24–26, Kyoto / Booth E-03
Featuring:
🔬 genO-panhCD3 — T-cell engager models
🔬 genO-hFcγR — Fc-mediated antibody function
Come talk models with our team!
#genOway #ImmunoOncology #JCA

@vanjohn10.bsky.socialSep 17, 2026, 5:25 PM

Tuhura is developing IFx-2.0 in Merkel cell carcinoma. If it successfully shows synergy with checkpoint inhibitors, it could become the new standard of care. Join CEO James Bianco as he explains the program's objectives.
$HURA
#ImmunoOncology #CancerResearch #LifeSciences
youtube.com/shorts/erD62...

@ascopost.bsky.socialSep 16, 2026, 2:10 PM

🖥️ Quantum computing may help advance precision #immunooncology.

A new quantum machine learning framework (Q-CHIPP) improved prediction of antigen presentation and immunotherapy response vs traditional methods.

▪️Tyler J. Alban, PhD

Learn more ➡️ https://ow.ly/mNEk50ZxyvT

@vanjohn10.bsky.socialSep 14, 2026, 6:33 PM

Earlier today, TuHURA Biosciences announced that the FDA had cleared its IND for TBS-2025. Join CEO Dr. James A. Bianco, MD as he explains the rationale behind pursuing VISTA.
youtube.com/shorts/HJb6J...
$HURA #ImmunoOncology #CancerResearch #LifeSciences
ir.tuhurabio.com/news-events/...

@carlus-2024.bsky.socialSep 11, 2026, 12:09 PM

September 11, 2026
👉 What if pancreatic cancer used… the blood-clotting system to protect itself from the immune system?
🙂 Another encouraging news from Groupe UIG.
Read: www.mountsinai.org/about/newsro...
#Cancer #PancreaticCancer #Immunotherapy #ImmunoOncology #Oncology #CancerResearch

@carlus-2024.bsky.socialSep 11, 2026, 12:05 PM

11 septembre 2026
👉 Et si le cancer du pancréas utilisait… le système de coagulation pour se protéger du système immunitaire?
🙂 Une autre nouvelle encourageante du Groupe UIG.
Lire: www.mountsinai.org/about/newsro...
#Cancer #PancreaticCancer #Immunotherapy #ImmunoOncology #Oncology

@fiosgenomics.bsky.socialSep 10, 2026, 7:30 AM

In this blog we demonstrate how #bioinformatics analysis is beneficial for the assessment of novel immuno-oncology therapies. Read it now!
https://www.fiosgenomics.com/using-bioinformatics-to-assess-novel-immuno-oncology-therapies/
#oncology #immunooncology

@carlus-2024.bsky.socialSep 9, 2026, 10:51 AM

September 9, 2026
👉 What if fewer CAR-T cells could sometimes deliver… greater efficacy?
🙂 Another encouraging news from Groupe UIG.
Read: medicalxpress.com/news/2026-09...
#CAR_T #CARtherapy #CancerResearch #Immunotherapy #ImmunoOncology

@estroradiotherapy.bsky.socialSep 7, 2026, 5:01 PM

Myth vs. Fact in Small Cell #LungCancer! 💡
For #WRAD2026, Dr Nicolas Pourel breaks down modern #SCLC treatment: #IMRT/#VMAT, low side effects, dose escalation & #ImmunoOncology.
🎥 Watch: https://bit.ly/467gmhZ
#Radonc #LungCancer

@j-cardio-oncol.bsky.socialSep 5, 2026, 3:24 PM

New systematic review & meta-analysis: PD-1/PD-L1 inhibitor combos vs controls raise CV adverse event risk, highest in targeted combos, with elevated risk in lung, multiple myeloma, urothelial and head/neck cancer patients. #CardioOncology #ImmunoOncology https://doi.org/10.1097/co9.0000000000000021

@carlus-2024.bsky.socialSep 5, 2026, 12:25 PM

September 5, 2026
👉 What if we could make cancer cells vulnerable to immunotherapy again?
🙂 Another encouraging news from Groupe UIG.
Read: lnkd.in/gwMarPZs
#CancerResearch #Immunotherapy #ImmunoOncology #PrecisionMedicine #Oncology #Biotech